Current and future therapeutic strategies to treat ataxia telangiectasia

Bibliography

• Boder E. Ataxia-telangiectasia: an overview. Kroc Found Ser 1985;19:1-63
   PubMedGoogle Scholar
• Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-53
   PubMed Web of Science ®Google Scholar
• Buoni S, Zannolli R, Sorrentino L, et al. Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia. Arch Neurol 2006;63:1479-82
   PubMedGoogle Scholar
• Broccoletti T, Del Giudice E, Amorosi S, et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. Eur J Neurol 2008;15:223-8
   PubMed Web of Science ®Google Scholar
• Broccoletti T, Del Giudice E, Cirillo E, et al. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur J Neurol 2011;18:564-70
   PubMed Web of Science ®Google Scholar
• Russo I, Cosentino C, Del Giudice E, et al. In ataxia-telangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol 2009;16:755-9
   PubMed Web of Science ®Google Scholar
• Zannolli R, Buoni S, Betti G, et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord 2012;27:1312-16
   PubMed Web of Science ®Google Scholar
• Gazulla J, Benavente I, Sarasa M. New therapies for ataxia-telangiectasia. Arch Neurol 2007;64:607-8
   PubMedGoogle Scholar
• Nissenkorn A, Hassin-Baer S, Lerman SF, et al. Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate. J Child Neurol 2013;28:155-60
   PubMed Web of Science ®Google Scholar
• Chessa L, Leuzzi V, Plebani A, et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia telangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis 2014;9:5
   PubMed Web of Science ®Google Scholar
• Gotoff SP, Amirmokri E, Liebner EJ. Ataxia telangiectasia. Neoplasia, untoward response to x-irradiation, and tuberous sclerosis. Am J Dis Child 1967;114:617-25
   PubMedGoogle Scholar
• Verhagen MM, Abdo WF, Willemsen MA, et al. Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology 2009;73:430-7
   PubMed Web of Science ®Google Scholar
• Brown KD, Ziv Y, Sadanandan SN, et al. The ataxia-telangiectasia gene product, a constitutively expressed nuclear protein that is not upregulated following genome damage. Proc Natl Acad Sci USA 1997;94:1840-5
   PubMed Web of Science ®Google Scholar
• McKinnon PJ. Maintaining genome stability in the nervous system. Nat Neurosci 2013;16:1523-9
   PubMed Web of Science ®Google Scholar
• Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004;3:1187-96
   PubMed Web of Science ®Google Scholar
• Syllaba L, Henner K. Contribution à l’independence de l’athetose double idiopathique et congenitale. Atteinte familiale, syndrome dystrophique, signe du reseau vasculaire conjonctival, integrité psychique. Rev Neurol 1926;1:541-62
   Google Scholar
• Louis-Bar D. Sur un syndrome progressif comprenant des telangiectasies capillaries cutanees et conjunctivales symetriques, à disposition naevode et de troubles cerebelleux. Confin Neurol 1941;4:32-42
   Google Scholar
• Boder E, Sedgwick RP. Ataxia-telangiectasia. A familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. A preliminary report on 7 children, an autopsy, and a case history. Univ Soc Calif Med Bull 1957;9:15-28
   Google Scholar
• Chessa L, Lisa A, Fiorani O, Zei G. Ataxia telangiectasia in Italy: genetic analysis. Int J Rad Biol 1994;66:S31-3
   PubMed Web of Science ®Google Scholar
• Chessa L, Polizzi A, Ruggieri M. Ataxia-telangiectasia. In: Ruggieri M, Pascual-Castroviejo I, Di Rocco C, editors. Neurocutaneous diseases. Phakomatosis and hamartoneoplastic syndromes. SpringerWienNewYork; 2008. p. 731-58
   Google Scholar
• Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol 2003;10:173-82
   PubMedGoogle Scholar
• Fiorilli M, Carbonari M, Crescenzi M, et al. T-cell receptor genes and ataxia-telangiectasia. Nature 1985;313:186
   PubMed Web of Science ®Google Scholar
• Giovanetti A, Mazzetta F, Caprini E, et al. Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood 2002;100:4082-9
   PubMed Web of Science ®Google Scholar
• Bastianon V, Fiorilli M, Giglioni E, et al. Cardiac anomalies in ataxia-telangiectasia. Am J Dis Child 1993;147:20-1
   PubMedGoogle Scholar
• Hasegawa S, Imai K, Yoshida K, et al. Whole-exome sequence analysis of ataxia telangiectasia-like phenotype. J Neurol Sci 2014;340:86-90
   PubMed Web of Science ®Google Scholar
• Chessa L, Piane M, Prudente S, et al. Molecular prenatal diagnosis of ataxia telangiectasia heterozygosity by direct mutational assays. Prenat Diagn 1999;19:542-5
   PubMed Web of Science ®Google Scholar
• Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 1988;336:577-80
   PubMed Web of Science ®Google Scholar
• Leiden Open Variation Database. Available from: http://chromium.liacs.nl/LOVD2/home.php?select_db=ATM [Last accessed 18 July 2014]
   Google Scholar
• Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 2013;14:197-210
   Web of Science ®Google Scholar
• Yang Y, Herrup K. Loss of neuronal cell cycle control in ataxia-telangiectasia: a unified disease mechanism. J Neurosci 2005;25:2522-9
   PubMed Web of Science ®Google Scholar
• Oricchio E, Saladino C, Iacovelli S, et al. ATM is activated by default in mitosis, localizes at centrosomes and monitors mitotic spindle integrity. Cell Cycle 2006;5:88-92
   PubMed Web of Science ®Google Scholar
• Gilad S, Chessa L, Khosravi R, et al. Genotype-phenotype relationships in ataxia-telangiectasia (A-T) and A-T variants. Am J Hum Genet 1998;62:551-61
   PubMed Web of Science ®Google Scholar
• Delia D, Piane M, Buscemi G, et al. Mre11 mutations and impaired ATM-dependent responses in an Italian family with ataxia telangiectasia like disorder (ATLD). Hum Mol Genet 2004;13:2155-63
   PubMed Web of Science ®Google Scholar
• Le Ber I, Moreira MC, Rivaud-Péchoux S, et al. Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies. Brain 2003;126:2761-72
   PubMed Web of Science ®Google Scholar
• Criscuolo C, Chessa L, Di Giandomenico S, et al. Ataxia with oculomotor apraxia type 2: a clinical, pathologic and genetic study. Neurology 2006;66:1207-10
   PubMed Web of Science ®Google Scholar
• Mosesso P, Piane M, Palitti F, et al. The novel human gene aprataxin is involved in the DNA single strand break repair complex. Cell Mol Life Sci 2005;62:485-91
   PubMed Web of Science ®Google Scholar
• De Amicis A, Piane M, Ferrari F, et al. Role of senataxin in DNA damage and telomeric stability. DNA Repair (Amst) 2011;10:199-209
   Google Scholar
• Fogel BL, Cho E, Wahnich A, et al. Mutation of senataxin alters disease-specific transcriptional networks in patients with ataxia with oculomotor apraxia type 2. Hum Mol Genet 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Richard P, Feng S, Manley JL. A SUMO-dependent interaction between Senataxin and the exosome, disrupted in the neurodegenerative disease AOA2, targets the exosome to sites of transcription-induced DNA damage. Genes Dev 2013;27:2227-32
   PubMed Web of Science ®Google Scholar
• Kuang X, Yan M, Liu N, et al. Control of Atm -/- thymic lymphoma cell proliferation in vitro and in vivo by dexamethasone. Cancer Chemother Pharmacol 2005;55:203-12
   PubMed Web of Science ®Google Scholar
• Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-45
   PubMed Web of Science ®Google Scholar
• Reichenbach J, Schubert R, Schindler D, et al. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Signal 2002;4:465-9
   PubMed Web of Science ®Google Scholar
• Reliene R, Schiestl RH. Experimental antioxidant therapy in ataxia telangiectasia. Clin Med Oncol 2008;2:431-6
   PubMedGoogle Scholar
• Degan P, d’Ischia M, Pallardó FV, et al. Glutathione levels in blood from ataxia telangiectasia patients suggest in vivo adaptive mechanisms to oxidative stress. Clin Biochem 2007;40:666-70
   PubMed Web of Science ®Google Scholar
• Browne SE, Roberts LJ II, Dennery PA, et al. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radic Biol Med 2004;36:938-42
   PubMed Web of Science ®Google Scholar
• Guo Z, Deshpande R, Paull TT. ATM activation in the presence of oxidative stress. Cell Cycle 2010;9:4805-11
   PubMed Web of Science ®Google Scholar
• Guo Z, Kozlov S, Lavin MF, et al. ATM activation by oxidative stress. Science 2010;330:517-21
   PubMed Web of Science ®Google Scholar
• Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 2011;30:546-55
   PubMed Web of Science ®Google Scholar
• Shackelford RE, Manuszak RP, Johnson CD, et al. Desferrioxamine treatment increases the genomic stability of Ataxia-telangiectasia cells. DNA Repair (Amst) 2003;2:971-81
   PubMed Web of Science ®Google Scholar
• Shackelford RE, Manuszak RP, Johnson CD, et al. Iron chelators increase the resistance of Ataxia telangiectasia cells to oxidative stress. DNA Repair (Amst) 2004;3:1263-72
   PubMed Web of Science ®Google Scholar
• Lai C-H, Chun HH, Nahas SA, et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci USA 2004;101:15676-81
   PubMed Web of Science ®Google Scholar
• Du L, Damoiseaux R, Nahas S, et al. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J Exp Med 2009;206:2285-97
   PubMed Web of Science ®Google Scholar
• Du L, Jung ME, Damoiseaux R, et al. A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. Mol Ther 2013;21:1653-60
   PubMed Web of Science ®Google Scholar
• Du L, Gatti RA. Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases. J Immunol Methods 2011;365:1-7
   PubMed Web of Science ®Google Scholar
• Nakamura K, Du L, Tunuguntla R, et al. Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia-telangiectasia. Hum Mutat 2012;33:198-208
   PubMed Web of Science ®Google Scholar
• Cavalieri S, Pozzi E, Gatti RA, Brusco A. Deep-intronic ATM mutation detected by genomic resequencing and corrected in vitro by antisense morpholino oligonucleotide (AMO). Eur J Hum Genet 2013;21:774-8
   PubMed Web of Science ®Google Scholar
• Gatti RA. SMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic models. Ann NY Acad Sci 2012;1250:33-40
   PubMed Web of Science ®Google Scholar
• Lee P, Martin NT, Nakamura K, et al. SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs. Nat Commun 2013;4:1824
   PubMed Web of Science ®Google Scholar
• Hu H, Gatti RA. MicroRNAs: new players in the DNA damage response. J Mol Cell Biol 2011;3:151-8
   PubMed Web of Science ®Google Scholar
• Martin NT, Nakamura K, Davies R, et al. ATM–dependent MiR-335 targets CtIP and modulates the DNA damage response. PLos Genetics 2013;9:e1003505
   PubMed Web of Science ®Google Scholar
• Harms C, Albrecht K, Harms U, et al. Phosphatidylinositol 3-Akt-kinase-dependent phosphorylation of p21(Waf1/Cip1) as a novel mechanism of neuroprotection by glucocorticoids. J Neurosci 2007;27:4562-71
   PubMed Web of Science ®Google Scholar
• Stahn C, Löwenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007;275:71-8
   PubMed Web of Science ®Google Scholar
• Hoijman E, Rocha-Viegas L, Kalko SG, et al. Glucocorticoid alternative effects on proliferating and differentiated mammary epithelium are associated to opposite regulation of cell-cycle inhibitor expression. J Cell Physiol 2012;227:1721-30
   PubMed Web of Science ®Google Scholar
• Buoni S, Zannolli R, Sorrentino L, Fois A. Reply to Gazzulla et al. Arch Neurol 2007;64:608-9
   Google Scholar
• Quarantelli M, Giardino G, Prinster A, et al. Steroid treatment in ataxia-telangiectasia induces alterations of functional magnetic resonance imaging during pronosupination task. Eur J Paediatr Neurol 2012;17:135-40
   PubMed Web of Science ®Google Scholar
• Giardino G, Fusco A, Romano R, et al. Betamethasone therapy in ataxia telangiectasia: unraveling the rationale of this serendipitous observation on the basis of the pathogenesis. Eur J Neurol 2013;20:740-7
   PubMed Web of Science ®Google Scholar
• Magnani M, Rossi L, D’Ascenzo M, et al. Erythrocyte engineering for drug delivery and targeting. Biotechnol Appl Biochem 1998;28:1-6
   PubMed Web of Science ®Google Scholar
• Magnani M, Rossi L. Approaches to erythrocyte-mediated drug delivery. Expert Opin Drug Deliv 2014;11:677-87
   PubMed Web of Science ®Google Scholar
• Rossi L, Castro M, D’Orio F, et al. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. Blood Cells Mol Dis 2004;33:57-63
   PubMed Web of Science ®Google Scholar
• Castro M, Rossi L, Papadatou B, et al. Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease. J Pediatr Gastroenterol Nutr 2007;44:423-6
   PubMed Web of Science ®Google Scholar
• Bossa F, Latiano A, Rossi L, et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol 2008;103:2509-16
   PubMed Web of Science ®Google Scholar
• Menotta M, Biagiotti S, Bianchi M, et al. Dexamethasone partially rescues ataxia telangiectasia-mutated (ATM) deficiency in ataxia telangiectasia by promoting a shortened protein variant retaining kinase activity. J Biol Chem 2012;287:41352-63
   PubMed Web of Science ®Google Scholar
• Barzilai A. The interrelations between malfunctioning DNA damage response (DDR) and the functionality of the neuro-glio-vascular unit. DNA Repair (Amst) 2013;12:543-57
   PubMed Web of Science ®Google Scholar
• Biagiotti S, Menotta M, Giacomini E, et al. Forward subtractive libraries containing genes transactivated by dexamethasone in ataxia-telangiectasia lymphoblastoid cells. Mol Cell Biochem 2014;392:13-30
   PubMed Web of Science ®Google Scholar
• Liston C, Gan W-B. Glucocorticoids are critical regulators of dendritic spine development and plasticity in vivo. Proc Natl Acad Sci USA 2011;108:16074-9
   PubMed Web of Science ®Google Scholar